Improving phase II oncology trials using best observed RECIST response as an endpoint by modelling continuous tumour measurements. (2017)

First Author: Lin CJ

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1002/sim.7453

PubMed Identifier: 28850689

Publication URI: http://europepmc.org/abstract/MED/28850689

Type: Journal Article/Review

Volume: 36

Parent Publication: Statistics in medicine

Issue: 29

ISSN: 0277-6715